Sen. Reed Leads Bipartisan Push to Fund Life-Saving Stem Cell and Cord Blood Programs Through 2031
This bill has been approved by the Senate committee and is now waiting for a vote by the full Senate. It is currently placed on the legislative calendar and is actively moving through the process. There are no other scheduled actions at this time.
This program has strong support from both parties and is a routine update to a successful health initiative that has been around for decades.
Patients with blood cancers like leukemia, lymphoma, and other serious blood disorders rely on the national bone marrow and cord blood registry to find matching donors for life-saving transplants. This bill keeps that registry funded and operating through 2031, and improves the quality and availability of cord blood units, giving these patients a better chance of finding a match.
“$33,009,000 for each of fiscal years 2027 through 2031”
Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.
The bill is now on the schedule for the full chamber to consider. It's in line for debate and a vote.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1093)
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
Rep. Gus Bilirakis led the unanimous passage of the Stem Cell Therapeutic and Research Reauthorization Act (HR 5160) through the House Health Subcommittee. The bill reauthorizes more than $280 million over five years for national cord blood and bone marrow transplant programs.
A bipartisan team of U.S. senators introduced legislation to renew funding for the C.W. Bill Young Cell Transplantation Program. The Stem Cell Therapeutic and Research Reauthorization Act of 2026 would run for five more years, connecting patients with unrelated donors for stem cell transplants.
The Senate HELP Committee advanced S. 4109, the Stem Cell Therapeutic and Research Reauthorization Act, which would reauthorize the C.W. Bill Young Cell Transplantation Program at $33,009,000 for FY 2027–2031 and the National Cord Blood Inventory through FY 2031. Passed en bloc with 22 yeas.
Document Type
Congressional Bill
Official Title
Stem Cell Therapeutic and Research Reauthorization Act of 2026
Analysis generated by AI. Always verify with official sources.